In 122 adults with severe oral corticosteroid-dependent asthma, tezepelumab gave greater oral corticosteroid dose reduction at week 28 than placebo while maintaining control (OR 2·93; p=0·0034). Trial stopped early (122 of 207 planned); exacerbations 30% vs 59%.
RCTn = 122
Wechsler et al. Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial